{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:39:31Z","timestamp":1791059971770,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":5272,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["C03\/010"],"award-info":[{"award-number":["C03\/010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["G03\/179"],"award-info":[{"award-number":["G03\/179"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.exphem.2007.08.012","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T09:52:08Z","timestamp":1196157128000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Esther","family":"Moga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Cant\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2007.08.012_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","article-title":"Rituximab: expanding role in therapy for lymphomas and autoimmune diseases","volume":"55","author":"Rastetter","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.exphem.2007.08.012_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib3","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib5","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib9","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib11","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V94.12.4220","article-title":"Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations","volume":"94","author":"Lehrnbecher","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2007.08.012_bib13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib14","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2007.08.012_bib15","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2005.1.329","article-title":"Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy","author":"Friedberg","year":"2005","journal-title":"Hematology. (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.exphem.2007.08.012_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0093-7754(03)00235-5","article-title":"Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab","volume":"30","author":"Dillman","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.exphem.2007.08.012_bib18","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses","volume":"16","author":"Gately","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.immunol.17.1.189","article-title":"Natural killer cells in antiviral defense: function and regulation by innate cytokines","volume":"17","author":"Biron","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1521-6616(03)00202-X","article-title":"Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates","volume":"109","author":"Verthelyi","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4049\/jimmunol.175.3.1619","article-title":"CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells","volume":"175","author":"Roda","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib25","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib26","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002371-199603000-00002","article-title":"Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas","volume":"19","author":"Funakoshi","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib28","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib29","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.4049\/jimmunol.167.6.3129","article-title":"Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2\u00a0and IL-15","volume":"167","author":"Dunne","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib30","first-page":"1002","article-title":"Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2","volume":"88","author":"Golay","year":"2003","journal-title":"Haematologica"},{"issue":"18 Pt 1","key":"10.1016\/j.exphem.2007.08.012_bib31","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-04-0525","article-title":"Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study","volume":"10","author":"Eisenbeis","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib32","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","article-title":"Phase I studies of interleukin (IL)-2\u00a0and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response","volume":"10","author":"Gluck","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/cimm.1995.1216","article-title":"Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2","volume":"165","author":"Munger","year":"1995","journal-title":"Cell Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib34","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V87.7.2632.bloodjournal8772632","article-title":"Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells","volume":"87","author":"Mrozek","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.1998.tb01229.x","article-title":"Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems","volume":"165","author":"Williams","year":"1998","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2007.08.012_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1359-6101(01)00021-1","article-title":"Interleukin-2 and interleukin-15: immunotherapy for cancer","volume":"13","author":"Fehniger","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.exphem.2007.08.012_bib37","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","article-title":"Interleukin (IL) 15 is\u00a0a novel cytokine that activates human natural killer cells via components of the IL-2 receptor","volume":"180","author":"Carson","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2007.08.012_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2007.08.012_bib39","first-page":"3577","article-title":"Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2005-11-4535","article-title":"Tumor growth impedes natural-killer-cell maturation in the bone marrow","volume":"108","author":"Richards","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1525-0016(03)00222-3","article-title":"Interleukin (IL)-21 and IL-15\u00a0genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma","volume":"8","author":"Kishida","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2007.08.012_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10555-005-6192-2","article-title":"Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies","volume":"24","author":"Iannello","year":"2005","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.exphem.2007.08.012_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00002371-200501000-00006","article-title":"Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells","volume":"28","author":"Ozdemir","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.exphem.2007.08.012_bib44","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2006-07-037846","article-title":"Molecular analysis of the methylprednisolone-mediated inhibition of NK cell function: evidence for different susceptibility of IL-2-versus IL-15-activated NK cells","volume":"109","author":"Chiossone","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib45","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA","volume":"157","author":"Ballas","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib46","first-page":"5595","article-title":"CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations","volume":"63","author":"van Ojik","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2007.08.012_bib47","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1073\/pnas.0403744101","article-title":"CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells","volume":"101","author":"Sivori","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2007.08.012_bib48","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.163.7.3642","article-title":"Oligodeoxynucleotides containing palindrome sequences with internal 5\u2032-CpG-3\u2032 act directly on human NK and activated T cells to induce IFN-gamma production in vitro","volume":"163","author":"Iho","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2007.08.012_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib50","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.08.012_bib51","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X07005206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X07005206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:25:06Z","timestamp":1759566306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X07005206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0301472X07005206"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2007.08.012","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2007.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}